Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jan 3;11:74. doi: 10.1038/s41467-019-13771-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 6 — a Relative gene expression of MCL1 and BCLXL detected by qRT-PCR in 4 ALK-rearranged lung cancer cell lines (n = 4 independent experiments). Significance was evaluated using a one-way ANOVA followed by Sidak’s test. b Evaluation of Mcl-1 expression, Bcl-xL expression, and YAP phosphorylation (pS127). Cell lysates were blotted using an immunoblotting assay with the indicated antibody. c Initial survival rate (top) and apoptosis activity (bottom) of KTOR1 (left) and KTOR2 (right) when cells were exposed to ALC or vehicle in combination with the knockdown of MCL1 and BCLXL. Summarized results are shown in the panels. The number of independent experiments is shown in each panel. Complete results are presented in Supplementary Fig. 6c, d. Significance was evaluated using a one-way ANOVA followed by Sidak’s test. d–e Increases in Mcl-1 and Bcl-xL expression were canceled by the inhibition of YAP1. YAP1 activity was inhibited using siRNA (d) or verteporfin (e). Traced experiments using H2228 are shown in Supplementary Fig. 6f, g. f Sequence analysis of putative YAP1/TEAD binding sites (labeled as A, B) in the upstream regions of MCL1 and BCLXL. The ChIP-PCR primer pairs designed were shown as arrows. g ChIP-qPCR on KTOR1 and KTOR2, which confirmed the presence of YAP1/TEAD binding sites in the MCL1 and BCLXL upstream regions and increased binding induced by the ALC treatment. BCLXL, a known YAP target, was also used as a positive control. Results are expressed as Percent Input (Two biologically independent cells, two-independent primers, two-independent experiment in each cell lines and two-independent qRT-PCR quantification in each experiment). The titration of DNA digestion, electrophoresis of input samples, and specificity of ChIP-qRT-PCR primers were shown in Supplementary Fig. 8. Significance was evaluated using a one-way ANOVA followed by Sidak’s multiple comparison test. h Schematic explanation of Fig. 6. The inhibition of YAP1 down-regulated Mcl-1 and Bcl-xL expression. The inhibition of both Mcl-1 and Bcl-xL induced apoptosis and inhibited initial survival. ALC alectinib, DMSO dimethyl sulfoxide, VER verteporfin, siSC si scramble control. Error bars indicate ± S.D. *P < 0.05.